Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | IL-6 receptor antibody for rheumatoid arthritis, giant cell arteritis and cytokine storm. | Biologic injection for arthritis, IBD and psoriasis. |
| Body system | Joints & Immunity | Joints & Immunity |
| Drug class | Interleukin inhibitors | TNF inhibitors |
| Supply | Prescription onlyWHO essential medicine | Prescription only |
| Main uses | Rheumatoid arthritis, Giant cell arteritis, Systemic juvenile arthritis, Cytokine release syndrome, Severe COVID-19 (selected patients) | Rheumatoid and psoriatic arthritis, Ankylosing spondylitis, Crohn's disease and ulcerative colitis, Psoriasis, Hidradenitis suppurativa |
| How it works | Blocks an inflammation signal called IL-6. | Mops up a key inflammation signal. |
| Starts working | Weeks | — |
| Half-life | Dose-dependent, up to about 2 weeks | About 2 weeks |
| Typical adult dose | 162 mg subcutaneously weekly or every two weeks; or 8 mg/kg IV every 4 weeks. | 40 mg under the skin every other week (some conditions start higher or go weekly). |
| Forms | Subcutaneous injection, IV infusion | Pre-filled pen, Pre-filled syringe |
| Common side effects | Upper respiratory infections, Headache, Raised liver enzymes, Raised cholesterol, Injection site reactions | Injection-site reactions, Upper respiratory infections, Headache |
| Serious side effects | Serious infections including TB, Bowel perforation, Low blood counts, Liver injury | Serious infections including TB reactivation, Lymphoma (rare), Demyelination, Heart failure worsening |
| Don't take if | Active serious infection; Active TB | — |
| Alcohol | Best to limit. Alcohol adds to liver strain. | — |
| Pregnancy | Use with cautionLimited data; avoid unless needed. | Use with cautionOften continued into pregnancy for IBD; baby's live vaccines may be delayed. |
| Breastfeeding | Use with cautionLimited data. | — |
| In use since | — | 2002 |
| Brand names | United States: Actemra, TofidenceUnited Kingdom: RoActemraIndia: Actemra, Tocilizumab biosimilars (Bmab etc.) | United States: Humira, Hadlima, Hyrimoz, YuflymaUnited Kingdom: Humira, Amgevita, Imraldi, YuflymaIndia: Exemptia, Adfrar |
| Legal status | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule H | — |
| ATC code | L04AC07 | L04AB04 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker